Wyeth taps Jane Seymour for European RA campaign

Share this article:
Wyeth taps Jane Seymour for European RA campaign
Wyeth taps Jane Seymour for European RA campaign
Wyeth enlisted actress and artist Jane Seymour for an unbranded rheumatoid arthritis (RA) campaign in Europe.

Seymour, known in the US for her role in Dr. Quinn, Medicine Woman, will host the campaign's first “My Day for RA” event tonight in Spain, where people with RA from all over Europe are invited to share their stories about living with the condition, according to a release.

The campaign was launched in conjunction with a website encouraging patients to enroll in an “action plan” for controlling RA. Upon the completion of a questionnaire, patients will receive a “personalized action plan with your short- and long-term goals and step by step plan to help you address your current life with RA and plan for your future with RA,” according to the site. PR for the campaign is handled by OgilvyHealthPR. 

Wyeth and Amgen co-market the blockbuster RA treatment Enbrel (etanercept) in the US and Canada, and Wyeth markets the product exclusively outside of the US. Wyeth doesn't currently market any other products for the condition, according to a Wyeth spokesperson. Pfizer, Wyeth's new parent, is currently in Phase 3 with an oral JAK-3 inhibitor for RA, listed as CP-690,550. Branded consumer marketing for prescription drugs in Europe is illegal.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...